Atrial Natriuretic Peptide (1-28), rat CAS NO.88898-17-3
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Atrial Natriuretic Peptide (1-28), rat |
| CAS NO. | 88898-17-3 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C128H205N45O39S2 |
| Molecular Weight | 3062.47g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water, phosphate-buffered saline (PBS), or dilute acetic acid (e.g., 0.1% v/v). It is recommended to prepare a stock solution at 0.1–1.0 mg/mL in 0.1% acetic acid or sterile water, then dilute to the working concentration with assay buffer |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Rat ANP (1-28) is the full-length bioactive peptide that binds to and activates natriuretic peptide receptor A (NPR-A), stimulating intracellular cGMP production. It exerts potent vasodilatory, natriuretic, diuretic, and aldosterone-suppressing activities. Bioactivity can be validated by cGMP accumulation assays in NPR-A-expressing cells or in vitro vascular relaxation assays. |
| Storage Conditions | Lyophilized powder: Store at –20°C or below in a desiccated environment, protected from light. Reconstituted solution: Aliquot and store at ≤ –20°C; avoid repeated freeze-thaw cycles. For long-term storage, –80°C is recommended. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
The peptide exerts its biological effects primarily by binding to the natriuretic peptide receptor‑A (NPR‑A), a transmembrane guanylyl cyclase‑coupled receptor. Ligand‑receptor interaction stimulates intracellular guanylyl cyclase activity, leading to a rise in cyclic GMP (cGMP) levels and subsequent activation of cGMP‑dependent protein kinases. This signaling cascade promotes vasodilation, enhances renal sodium and water excretion (natriuresis and diuresis), and suppresses the renin‑angiotensin‑aldosterone system. Additionally, the peptide can bind to the clearance receptor NPR‑C, which modulates its plasma half‑life and tissue distribution. The disulfide bridge within the peptide is critical for maintaining the conformation required for high‑affinity receptor binding and full biological potency.
2.PRODUCT INDICATIONS
3.CLINICAL EFFICACY OF PRODUCT
As a research reagent, Atrial Natriuretic Peptide (1‑28), rat does not possess established clinical efficacy for therapeutic use in human patients. This synthetic peptide has not undergone clinical development or received regulatory approval for any medical indication. While native ANP and its analogs have been explored in clinical trials for conditions such as acute heart failure and hypertension, the present rat‑sequence product remains an investigational tool for basic and translational research. It has no proven clinical efficacy or safety profile in humans and is strictly intended for laboratory research applications.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
